Rivaroxaban 15mg

Indications of Rivaroxaban 15mg.

Prevention and therapy of pulmonary embolism and deep vein thrombosis; prevention of systemic thromboembolism and stroke in patients with non-valvular atrial fibrillation; prevention of death due to myocardial infarction and cardiovascular causes in patients after acute coronary syndrome, which occurred with the increase of cardiospecific biomarkers, together with acetylsalicylic acid or with acetylsalicylic acid and thienopyridine (ticlopidine, clopidogrel).

Method of application of Rivaroxaban 15mg and dose.

Rivaroxaban is taken internally, the dosage depends on the indications, the functional state of the kidneys, the liver and the blood coagulation system and is set individually.
It is necessary to use Rivaroxaban 15mg in the treatment of patients with an increased risk of bleeding, including uncontrolled severe arterial hypertension with caution; the presence of acquired or congenital diseases that lead to bleeding; recently suffered peptic ulcer of the gastrointestinal tract; exacerbation of peptic ulcer of the gastrointestinal tract; vascular retinopathy; intraspinal or intracerebral vascular pathology; recently suffered intracerebral or intracranial hemorrhage; recently transferred ophthalmologic or neurosurgical intervention.
The usage of Rivaroxaban 15mg in patients with severe and severe renal insufficiency (with creatinine clearance less than 15 ml / min) is not recommended.
Rivaroxaban 15mg used with caution in patients with moderate renal insufficiency (with creatinine clearance of 30-49 ml / min), which are concomitantly treated with remedies capable of increasing Rivaroxaban 15mg content in blood serum, as well as in patients with creatinine clearance of 15-30 ml / min . In patients with severe renal insufficiency, the level of Rivaroxaban 15mg in the blood serum can be greatly increased, this can lead to the development of bleeding.
Patients with severe renal insufficiency with an increased risk of bleeding and patients who receive systemic treatment with HIV protease inhibitors or antifungal agents of the azole group should be strictly controlled after the initiation of therapy to detect complications in the form of bleeding in a timely manner. Such monitoring may include careful monitoring of the surgical wound to be separated from the drainage, regular physical examination of the patient and periodic determination of the hemoglobin content.